Sys Medtech International Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 16-11-2024
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.10 Cr
as on 16-11-2024
- Satisfied Charges ₹ 4.45 M
as on 16-11-2024
- Revenue 19.59%
(FY 2023)
- Profit -8.60%
(FY 2023)
- Ebitda 6.05%
(FY 2023)
- Net Worth 20.25%
(FY 2023)
- Total Assets 14.34%
(FY 2023)
About Sys Medtech International
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹10.10 Cr. The company has closed loans amounting to ₹4.45 M, as per Ministry of Corporate Affairs (MCA) records.
Satish Singh and Yashoda Singh serve as directors at the Company.
- CIN/LLPIN
U74120MH2012PTC231151
- Company No.
231151
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 May 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sys Medtech International?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satish Singh  | Director | 16-May-2012 | Current |
| Yashoda Singh | Director | 16-May-2012 | Current |
Financial Performance of Sys Medtech International.
Sys Medtech International Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.59% increase. The company also saw a slight decrease in profitability, with a 8.6% decrease in profit. The company's net worth Soared by an impressive increase of 20.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sys Medtech International?
In 2023, Sys Medtech International had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Jun 2023 | ₹2.40 M | Open |
Others Creation Date: 02 Nov 2020 | ₹5.62 M | Open |
Others Creation Date: 29 Jun 2019 | ₹9.30 Cr | Open |
How Many Employees Work at Sys Medtech International?
Sys Medtech International has a workforce of 89 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sys Medtech International, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sys Medtech International's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
